BiopestPeptidV1, Main, Exploration, bibRecord, 001155

Interferon γ (IFNγ) Signaling via Mechanistic Target of Rapamycin Complex 2 (mTORC2) and Regulatory Effects in the Generation of Type II Interferon Biological Responses.

Identifieur interne : 001155 ( Main/Exploration ); précédent : 001154; suivant : 001156

Interferon γ (IFNγ) Signaling via Mechanistic Target of Rapamycin Complex 2 (mTORC2) and Regulatory Effects in the Generation of Type II Interferon Biological Responses.

Auteurs : Barbara Kroczynska [États-Unis] ; Robert L. Rafidi [États-Unis] ; Beata Majchrzak-Kita [Canada] ; Ewa M. Kosciuczuk [États-Unis] ; Gavin T. Blyth [États-Unis] ; Jacek Jemielity ; Zofia Warminska [Pologne] ; Diana Saleiro [États-Unis] ; Swarna Mehrotra [États-Unis] ; Ahmet Dirim Arslan [États-Unis] ; Eleanor N. Fish [Canada] ; Leonidas C. Platanias [États-Unis]

Source :

The Journal of biological chemistry [ 1083-351X ] ; 2016.

RBID : pubmed:26645692

Descripteurs français

English descriptors

Abstract

We provide evidence for a unique pathway engaged by the type II IFN receptor, involving mTORC2/AKT-mediated downstream regulation of mTORC1 and effectors. These events are required for formation of the eukaryotic translation initiation factor 4F complex (eIF4F) and initiation of mRNA translation of type II interferon-stimulated genes. Our studies establish that Rictor is essential for the generation of type II IFN-dependent antiviral and antiproliferative responses and that it controls the generation of type II IFN-suppressive effects on normal and malignant hematopoiesis. Together, our findings establish a central role for mTORC2 in IFNγ signaling and type II IFN responses.

DOI: 10.1074/jbc.M115.664995
PubMed: 26645692
PubMed Central: PMC4732221

Affiliations:

Canada, Pologne, États-Unis
Illinois

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 001304
to stream Main, to step Curation: 001304

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Interferon γ (IFNγ) Signaling via Mechanistic Target of Rapamycin Complex 2 (mTORC2) and Regulatory Effects in the Generation of Type II Interferon Biological Responses.</title>
<author><name sortKey="Kroczynska, Barbara" sort="Kroczynska, Barbara" uniqKey="Kroczynska B" first="Barbara" last="Kroczynska">Barbara Kroczynska</name>
<affiliation wicri:level="2"><nlm:affiliation>From the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, the Department of Radiation Oncology, Northwestern University, Chicago, Illinois 60611.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
<wicri:cityArea>From the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, the Department of Radiation Oncology, Northwestern University, Chicago</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Rafidi, Robert L" sort="Rafidi, Robert L" uniqKey="Rafidi R" first="Robert L" last="Rafidi">Robert L. Rafidi</name>
<affiliation wicri:level="2"><nlm:affiliation>From the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
<wicri:cityArea>From the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Majchrzak Kita, Beata" sort="Majchrzak Kita, Beata" uniqKey="Majchrzak Kita B" first="Beata" last="Majchrzak-Kita">Beata Majchrzak-Kita</name>
<affiliation wicri:level="1"><nlm:affiliation>the Toronto General Research Institute, University Health Network, and Department of Immunology, University of Toronto, Toronto, Ontario M5G 2MI, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>the Toronto General Research Institute, University Health Network, and Department of Immunology, University of Toronto, Toronto, Ontario M5G 2MI</wicri:regionArea>
<wicri:noRegion>Ontario M5G 2MI</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kosciuczuk, Ewa M" sort="Kosciuczuk, Ewa M" uniqKey="Kosciuczuk E" first="Ewa M" last="Kosciuczuk">Ewa M. Kosciuczuk</name>
<affiliation wicri:level="2"><nlm:affiliation>From the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, the Division of Hematology-Oncology, Department of Medicine, Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois 60612.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
<wicri:cityArea>From the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, the Division of Hematology-Oncology, Department of Medicine, Jesse Brown Veterans Affairs Medical Center, Chicago</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Blyth, Gavin T" sort="Blyth, Gavin T" uniqKey="Blyth G" first="Gavin T" last="Blyth">Gavin T. Blyth</name>
<affiliation wicri:level="2"><nlm:affiliation>From the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
<wicri:cityArea>From the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Jemielity, Jacek" sort="Jemielity, Jacek" uniqKey="Jemielity J" first="Jacek" last="Jemielity">Jacek Jemielity</name>
<affiliation><nlm:affiliation>the Centre of New Technologies, University of Warsaw, 02-097 Warsaw, Poland, and.</nlm:affiliation>
<wicri:noCountry code="subField">and</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Warminska, Zofia" sort="Warminska, Zofia" uniqKey="Warminska Z" first="Zofia" last="Warminska">Zofia Warminska</name>
<affiliation wicri:level="1"><nlm:affiliation>the Centre of New Technologies, University of Warsaw, 02-097 Warsaw, Poland, and the College of Inter-Faculty Individual Studies in Mathematics and Natural Sciences, University of Warsaw, 02-089 Warsaw, Poland.</nlm:affiliation>
<country xml:lang="fr">Pologne</country>
<wicri:regionArea>the Centre of New Technologies, University of Warsaw, 02-097 Warsaw, Poland, and the College of Inter-Faculty Individual Studies in Mathematics and Natural Sciences, University of Warsaw, 02-089 Warsaw</wicri:regionArea>
<wicri:noRegion>02-089 Warsaw</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Saleiro, Diana" sort="Saleiro, Diana" uniqKey="Saleiro D" first="Diana" last="Saleiro">Diana Saleiro</name>
<affiliation wicri:level="2"><nlm:affiliation>From the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
<wicri:cityArea>From the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Mehrotra, Swarna" sort="Mehrotra, Swarna" uniqKey="Mehrotra S" first="Swarna" last="Mehrotra">Swarna Mehrotra</name>
<affiliation wicri:level="2"><nlm:affiliation>From the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
<wicri:cityArea>From the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Arslan, Ahmet Dirim" sort="Arslan, Ahmet Dirim" uniqKey="Arslan A" first="Ahmet Dirim" last="Arslan">Ahmet Dirim Arslan</name>
<affiliation wicri:level="2"><nlm:affiliation>From the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
<wicri:cityArea>From the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Fish, Eleanor N" sort="Fish, Eleanor N" uniqKey="Fish E" first="Eleanor N" last="Fish">Eleanor N. Fish</name>
<affiliation wicri:level="1"><nlm:affiliation>the Toronto General Research Institute, University Health Network, and Department of Immunology, University of Toronto, Toronto, Ontario M5G 2MI, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>the Toronto General Research Institute, University Health Network, and Department of Immunology, University of Toronto, Toronto, Ontario M5G 2MI</wicri:regionArea>
<wicri:noRegion>Ontario M5G 2MI</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Platanias, Leonidas C" sort="Platanias, Leonidas C" uniqKey="Platanias L" first="Leonidas C" last="Platanias">Leonidas C. Platanias</name>
<affiliation wicri:level="1"><nlm:affiliation>From the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, the Division of Hematology-Oncology, Department of Medicine, Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois 60612, l-platanias@northwestern.edu.</nlm:affiliation>
<country wicri:rule="url">États-Unis</country>
<wicri:regionArea>From the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, the Division of Hematology-Oncology, Department of Medicine, Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois 60612</wicri:regionArea>
<wicri:noRegion>Illinois 60612</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:26645692</idno>
<idno type="pmid">26645692</idno>
<idno type="doi">10.1074/jbc.M115.664995</idno>
<idno type="pmc">PMC4732221</idno>
<idno type="wicri:Area/Main/Corpus">001304</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001304</idno>
<idno type="wicri:Area/Main/Curation">001304</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001304</idno>
<idno type="wicri:Area/Main/Exploration">001304</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Interferon γ (IFNγ) Signaling via Mechanistic Target of Rapamycin Complex 2 (mTORC2) and Regulatory Effects in the Generation of Type II Interferon Biological Responses.</title>
<author><name sortKey="Kroczynska, Barbara" sort="Kroczynska, Barbara" uniqKey="Kroczynska B" first="Barbara" last="Kroczynska">Barbara Kroczynska</name>
<affiliation wicri:level="2"><nlm:affiliation>From the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, the Department of Radiation Oncology, Northwestern University, Chicago, Illinois 60611.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
<wicri:cityArea>From the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, the Department of Radiation Oncology, Northwestern University, Chicago</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Rafidi, Robert L" sort="Rafidi, Robert L" uniqKey="Rafidi R" first="Robert L" last="Rafidi">Robert L. Rafidi</name>
<affiliation wicri:level="2"><nlm:affiliation>From the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
<wicri:cityArea>From the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Majchrzak Kita, Beata" sort="Majchrzak Kita, Beata" uniqKey="Majchrzak Kita B" first="Beata" last="Majchrzak-Kita">Beata Majchrzak-Kita</name>
<affiliation wicri:level="1"><nlm:affiliation>the Toronto General Research Institute, University Health Network, and Department of Immunology, University of Toronto, Toronto, Ontario M5G 2MI, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>the Toronto General Research Institute, University Health Network, and Department of Immunology, University of Toronto, Toronto, Ontario M5G 2MI</wicri:regionArea>
<wicri:noRegion>Ontario M5G 2MI</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kosciuczuk, Ewa M" sort="Kosciuczuk, Ewa M" uniqKey="Kosciuczuk E" first="Ewa M" last="Kosciuczuk">Ewa M. Kosciuczuk</name>
<affiliation wicri:level="2"><nlm:affiliation>From the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, the Division of Hematology-Oncology, Department of Medicine, Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois 60612.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
<wicri:cityArea>From the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, the Division of Hematology-Oncology, Department of Medicine, Jesse Brown Veterans Affairs Medical Center, Chicago</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Blyth, Gavin T" sort="Blyth, Gavin T" uniqKey="Blyth G" first="Gavin T" last="Blyth">Gavin T. Blyth</name>
<affiliation wicri:level="2"><nlm:affiliation>From the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
<wicri:cityArea>From the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Jemielity, Jacek" sort="Jemielity, Jacek" uniqKey="Jemielity J" first="Jacek" last="Jemielity">Jacek Jemielity</name>
<affiliation><nlm:affiliation>the Centre of New Technologies, University of Warsaw, 02-097 Warsaw, Poland, and.</nlm:affiliation>
<wicri:noCountry code="subField">and</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Warminska, Zofia" sort="Warminska, Zofia" uniqKey="Warminska Z" first="Zofia" last="Warminska">Zofia Warminska</name>
<affiliation wicri:level="1"><nlm:affiliation>the Centre of New Technologies, University of Warsaw, 02-097 Warsaw, Poland, and the College of Inter-Faculty Individual Studies in Mathematics and Natural Sciences, University of Warsaw, 02-089 Warsaw, Poland.</nlm:affiliation>
<country xml:lang="fr">Pologne</country>
<wicri:regionArea>the Centre of New Technologies, University of Warsaw, 02-097 Warsaw, Poland, and the College of Inter-Faculty Individual Studies in Mathematics and Natural Sciences, University of Warsaw, 02-089 Warsaw</wicri:regionArea>
<wicri:noRegion>02-089 Warsaw</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Saleiro, Diana" sort="Saleiro, Diana" uniqKey="Saleiro D" first="Diana" last="Saleiro">Diana Saleiro</name>
<affiliation wicri:level="2"><nlm:affiliation>From the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
<wicri:cityArea>From the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Mehrotra, Swarna" sort="Mehrotra, Swarna" uniqKey="Mehrotra S" first="Swarna" last="Mehrotra">Swarna Mehrotra</name>
<affiliation wicri:level="2"><nlm:affiliation>From the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
<wicri:cityArea>From the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Arslan, Ahmet Dirim" sort="Arslan, Ahmet Dirim" uniqKey="Arslan A" first="Ahmet Dirim" last="Arslan">Ahmet Dirim Arslan</name>
<affiliation wicri:level="2"><nlm:affiliation>From the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
<wicri:cityArea>From the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Fish, Eleanor N" sort="Fish, Eleanor N" uniqKey="Fish E" first="Eleanor N" last="Fish">Eleanor N. Fish</name>
<affiliation wicri:level="1"><nlm:affiliation>the Toronto General Research Institute, University Health Network, and Department of Immunology, University of Toronto, Toronto, Ontario M5G 2MI, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>the Toronto General Research Institute, University Health Network, and Department of Immunology, University of Toronto, Toronto, Ontario M5G 2MI</wicri:regionArea>
<wicri:noRegion>Ontario M5G 2MI</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Platanias, Leonidas C" sort="Platanias, Leonidas C" uniqKey="Platanias L" first="Leonidas C" last="Platanias">Leonidas C. Platanias</name>
<affiliation wicri:level="1"><nlm:affiliation>From the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, the Division of Hematology-Oncology, Department of Medicine, Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois 60612, l-platanias@northwestern.edu.</nlm:affiliation>
<country wicri:rule="url">États-Unis</country>
<wicri:regionArea>From the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, the Division of Hematology-Oncology, Department of Medicine, Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois 60612</wicri:regionArea>
<wicri:noRegion>Illinois 60612</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">The Journal of biological chemistry</title>
<idno type="eISSN">1083-351X</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals (MeSH)</term>
<term>Antiviral Agents (chemistry)</term>
<term>Antiviral Agents (metabolism)</term>
<term>Carrier Proteins (metabolism)</term>
<term>Chemokine CXCL10 (metabolism)</term>
<term>Eukaryotic Initiation Factor-4F (metabolism)</term>
<term>Fibroblasts (metabolism)</term>
<term>Gene Expression Regulation (MeSH)</term>
<term>Hematopoiesis (MeSH)</term>
<term>Hematopoietic Stem Cells (cytology)</term>
<term>Humans (MeSH)</term>
<term>Interferon-Stimulated Gene Factor 3, gamma Subunit (metabolism)</term>
<term>Interferon-gamma (metabolism)</term>
<term>Mechanistic Target of Rapamycin Complex 1 (MeSH)</term>
<term>Mechanistic Target of Rapamycin Complex 2 (MeSH)</term>
<term>Mice (MeSH)</term>
<term>Mice, Knockout (MeSH)</term>
<term>Multiprotein Complexes (metabolism)</term>
<term>Phosphorylation (MeSH)</term>
<term>Polyribosomes (metabolism)</term>
<term>Protein Biosynthesis (MeSH)</term>
<term>Rapamycin-Insensitive Companion of mTOR Protein (MeSH)</term>
<term>Receptors, Interferon (metabolism)</term>
<term>Signal Transduction (MeSH)</term>
<term>TOR Serine-Threonine Kinases (metabolism)</term>
<term>U937 Cells (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux (MeSH)</term>
<term>Antiviraux (composition chimique)</term>
<term>Antiviraux (métabolisme)</term>
<term>Biosynthèse des protéines (MeSH)</term>
<term>Cellules U937 (MeSH)</term>
<term>Cellules souches hématopoïétiques (cytologie)</term>
<term>Chimiokine CXCL10 (métabolisme)</term>
<term>Compagnon de mTOR insensible à la rapamycine (MeSH)</term>
<term>Complexe-1 cible mécanistique de la rapamycine (MeSH)</term>
<term>Complexe-2 cible mécanistique de la rapamycine (MeSH)</term>
<term>Complexes multiprotéiques (métabolisme)</term>
<term>Facteur-4F d'initiation eucaryote (métabolisme)</term>
<term>Fibroblastes (métabolisme)</term>
<term>Humains (MeSH)</term>
<term>Hématopoïèse (MeSH)</term>
<term>Interféron gamma (métabolisme)</term>
<term>Phosphorylation (MeSH)</term>
<term>Polyribosomes (métabolisme)</term>
<term>Protéines de transport (métabolisme)</term>
<term>Récepteur interféron (métabolisme)</term>
<term>Régulation de l'expression des gènes (MeSH)</term>
<term>Souris (MeSH)</term>
<term>Souris knockout (MeSH)</term>
<term>Sous-unité gamma du complexe ISGF3 (métabolisme)</term>
<term>Sérine-thréonine kinases TOR (métabolisme)</term>
<term>Transduction du signal (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Antiviral Agents</term>
<term>Carrier Proteins</term>
<term>Chemokine CXCL10</term>
<term>Eukaryotic Initiation Factor-4F</term>
<term>Interferon-Stimulated Gene Factor 3, gamma Subunit</term>
<term>Interferon-gamma</term>
<term>Multiprotein Complexes</term>
<term>Receptors, Interferon</term>
<term>TOR Serine-Threonine Kinases</term>
</keywords>
<keywords scheme="MESH" qualifier="composition chimique" xml:lang="fr"><term>Antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="cytologie" xml:lang="fr"><term>Cellules souches hématopoïétiques</term>
</keywords>
<keywords scheme="MESH" qualifier="cytology" xml:lang="en"><term>Hematopoietic Stem Cells</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Fibroblasts</term>
<term>Polyribosomes</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Antiviraux</term>
<term>Chimiokine CXCL10</term>
<term>Complexes multiprotéiques</term>
<term>Facteur-4F d'initiation eucaryote</term>
<term>Fibroblastes</term>
<term>Interféron gamma</term>
<term>Polyribosomes</term>
<term>Protéines de transport</term>
<term>Récepteur interféron</term>
<term>Sous-unité gamma du complexe ISGF3</term>
<term>Sérine-thréonine kinases TOR</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Gene Expression Regulation</term>
<term>Hematopoiesis</term>
<term>Humans</term>
<term>Mechanistic Target of Rapamycin Complex 1</term>
<term>Mechanistic Target of Rapamycin Complex 2</term>
<term>Mice</term>
<term>Mice, Knockout</term>
<term>Phosphorylation</term>
<term>Protein Biosynthesis</term>
<term>Rapamycin-Insensitive Companion of mTOR Protein</term>
<term>Signal Transduction</term>
<term>U937 Cells</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Biosynthèse des protéines</term>
<term>Cellules U937</term>
<term>Compagnon de mTOR insensible à la rapamycine</term>
<term>Complexe-1 cible mécanistique de la rapamycine</term>
<term>Complexe-2 cible mécanistique de la rapamycine</term>
<term>Humains</term>
<term>Hématopoïèse</term>
<term>Phosphorylation</term>
<term>Régulation de l'expression des gènes</term>
<term>Souris</term>
<term>Souris knockout</term>
<term>Transduction du signal</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We provide evidence for a unique pathway engaged by the type II IFN receptor, involving mTORC2/AKT-mediated downstream regulation of mTORC1 and effectors. These events are required for formation of the eukaryotic translation initiation factor 4F complex (eIF4F) and initiation of mRNA translation of type II interferon-stimulated genes. Our studies establish that Rictor is essential for the generation of type II IFN-dependent antiviral and antiproliferative responses and that it controls the generation of type II IFN-suppressive effects on normal and malignant hematopoiesis. Together, our findings establish a central role for mTORC2 in IFNγ signaling and type II IFN responses. </div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26645692</PMID>
<DateCompleted><Year>2016</Year>
<Month>06</Month>
<Day>15</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1083-351X</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>291</Volume>
<Issue>5</Issue>
<PubDate><Year>2016</Year>
<Month>Jan</Month>
<Day>29</Day>
</PubDate>
</JournalIssue>
<Title>The Journal of biological chemistry</Title>
<ISOAbbreviation>J Biol Chem</ISOAbbreviation>
</Journal>
<ArticleTitle>Interferon γ (IFNγ) Signaling via Mechanistic Target of Rapamycin Complex 2 (mTORC2) and Regulatory Effects in the Generation of Type II Interferon Biological Responses.</ArticleTitle>
<Pagination><MedlinePgn>2389-96</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1074/jbc.M115.664995</ELocationID>
<Abstract><AbstractText>We provide evidence for a unique pathway engaged by the type II IFN receptor, involving mTORC2/AKT-mediated downstream regulation of mTORC1 and effectors. These events are required for formation of the eukaryotic translation initiation factor 4F complex (eIF4F) and initiation of mRNA translation of type II interferon-stimulated genes. Our studies establish that Rictor is essential for the generation of type II IFN-dependent antiviral and antiproliferative responses and that it controls the generation of type II IFN-suppressive effects on normal and malignant hematopoiesis. Together, our findings establish a central role for mTORC2 in IFNγ signaling and type II IFN responses. </AbstractText>
<CopyrightInformation>© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kroczynska</LastName>
<ForeName>Barbara</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>From the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, the Department of Radiation Oncology, Northwestern University, Chicago, Illinois 60611.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Rafidi</LastName>
<ForeName>Robert L</ForeName>
<Initials>RL</Initials>
<AffiliationInfo><Affiliation>From the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Majchrzak-Kita</LastName>
<ForeName>Beata</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>the Toronto General Research Institute, University Health Network, and Department of Immunology, University of Toronto, Toronto, Ontario M5G 2MI, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kosciuczuk</LastName>
<ForeName>Ewa M</ForeName>
<Initials>EM</Initials>
<AffiliationInfo><Affiliation>From the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, the Division of Hematology-Oncology, Department of Medicine, Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois 60612.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Blyth</LastName>
<ForeName>Gavin T</ForeName>
<Initials>GT</Initials>
<AffiliationInfo><Affiliation>From the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Jemielity</LastName>
<ForeName>Jacek</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>the Centre of New Technologies, University of Warsaw, 02-097 Warsaw, Poland, and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Warminska</LastName>
<ForeName>Zofia</ForeName>
<Initials>Z</Initials>
<AffiliationInfo><Affiliation>the Centre of New Technologies, University of Warsaw, 02-097 Warsaw, Poland, and the College of Inter-Faculty Individual Studies in Mathematics and Natural Sciences, University of Warsaw, 02-089 Warsaw, Poland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Saleiro</LastName>
<ForeName>Diana</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>From the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mehrotra</LastName>
<ForeName>Swarna</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>From the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Arslan</LastName>
<ForeName>Ahmet Dirim</ForeName>
<Initials>AD</Initials>
<AffiliationInfo><Affiliation>From the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Fish</LastName>
<ForeName>Eleanor N</ForeName>
<Initials>EN</Initials>
<AffiliationInfo><Affiliation>the Toronto General Research Institute, University Health Network, and Department of Immunology, University of Toronto, Toronto, Ontario M5G 2MI, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Platanias</LastName>
<ForeName>Leonidas C</ForeName>
<Initials>LC</Initials>
<AffiliationInfo><Affiliation>From the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, the Division of Hematology-Oncology, Department of Medicine, Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois 60612, l-platanias@northwestern.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>R01 CA077816</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>I01 CX000916</GrantID>
<Acronym>CX</Acronym>
<Agency>CSRD VA</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>CA161796</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 CA161796</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 CA155566</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>CA77816</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>P30 CA060553</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>T32 CA080621</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>T32 CA070085</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>CA155566</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2015</Year>
<Month>12</Month>
<Day>08</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>J Biol Chem</MedlineTA>
<NlmUniqueID>2985121R</NlmUniqueID>
<ISSNLinking>0021-9258</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D054357">Chemokine CXCL10</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C485433">Cxcl10 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D039562">Eukaryotic Initiation Factor-4F</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C558681">IRF9 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050834">Interferon-Stimulated Gene Factor 3, gamma Subunit</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D046912">Multiprotein Complexes</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000076226">Rapamycin-Insensitive Companion of mTOR Protein</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017471">Receptors, Interferon</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C120411">interferon receptor, type II</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C525637">rictor protein, mouse</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>82115-62-6</RegistryNumber>
<NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D000076222">Mechanistic Target of Rapamycin Complex 1</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D000076225">Mechanistic Target of Rapamycin Complex 2</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D054357" MajorTopicYN="N">Chemokine CXCL10</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D039562" MajorTopicYN="N">Eukaryotic Initiation Factor-4F</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006410" MajorTopicYN="N">Hematopoiesis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006412" MajorTopicYN="N">Hematopoietic Stem Cells</DescriptorName>
<QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D050834" MajorTopicYN="N">Interferon-Stimulated Gene Factor 3, gamma Subunit</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000076222" MajorTopicYN="N">Mechanistic Target of Rapamycin Complex 1</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000076225" MajorTopicYN="N">Mechanistic Target of Rapamycin Complex 2</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D046912" MajorTopicYN="N">Multiprotein Complexes</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011132" MajorTopicYN="N">Polyribosomes</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014176" MajorTopicYN="N">Protein Biosynthesis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000076226" MajorTopicYN="N">Rapamycin-Insensitive Companion of mTOR Protein</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017471" MajorTopicYN="N">Receptors, Interferon</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020298" MajorTopicYN="N">U937 Cells</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">PI3K</Keyword>
<Keyword MajorTopicYN="N">antiviral agent</Keyword>
<Keyword MajorTopicYN="N">interferon</Keyword>
<Keyword MajorTopicYN="N">signal transduction</Keyword>
<Keyword MajorTopicYN="N">translation control</Keyword>
<Keyword MajorTopicYN="N">translation initiation factor</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year>
<Month>05</Month>
<Day>14</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2015</Year>
<Month>12</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2015</Year>
<Month>12</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>6</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">26645692</ArticleId>
<ArticleId IdType="pii">M115.664995</ArticleId>
<ArticleId IdType="doi">10.1074/jbc.M115.664995</ArticleId>
<ArticleId IdType="pmc">PMC4732221</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Pharmacol Ther. 2012 Jul;135(1):44-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22484806</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2014 Mar 7;289(10):6581-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24469448</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Clin Oncol. 2013 Oct;10(10):588-98</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23982524</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2002 Jun 15;168(12):5984-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12055203</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 1994 Jun 3;264(5164):1415-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8197455</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Genes Dev. 2004 Aug 15;18(16):1926-45</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15314020</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cytokine. 2009 Oct-Nov;48(1-2):138-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19682919</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2008 Mar 25;105(12):4808-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18339807</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Immunol. 2005 May;5(5):375-86</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15864272</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Immunol. 2012 Feb;12(2):125-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22222875</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2009 Apr 17;284(16):10301-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19211565</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2005 Feb 18;307(5712):1098-101</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15718470</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Rheumatol. 2010 Jan;6(1):40-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20046205</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2010 Feb;16(2):205-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20072130</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2013 Aug 31;382(9894):819-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23993191</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Leuk Res. 2013 Sep;37(9):1041-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23827351</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Mol Cell Biol. 2009 May;10(5):307-18</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19339977</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunity. 2012 Apr 20;36(4):503-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22520844</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Cell Biol. 2012 Jul;32(14):2809-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22586265</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Semin Cell Dev Biol. 2014 Dec;36:79-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25242279</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arthritis Res Ther. 2011;13(6):249</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22192711</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Genes Dev. 2006 Oct 15;20(20):2820-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17043309</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood. 2006 Oct 15;108(8):2509-19</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16778145</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cytokine Growth Factor Rev. 2011 Jun;22(3):121-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21802343</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Mol Cell Biol. 2011 Jan;12(1):21-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21157483</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Rep. 2015 Apr 28;11(4):605-17</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25892232</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Interferon Cytokine Res. 2013 Apr;33(4):143-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23570379</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2012 May 15;109(20):7723-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22550181</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Drug Discov. 2007 Dec;6(12):975-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18049472</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biomol Concepts. 2012 Apr;3(2):127-139</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23710261</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood. 2014 Oct 16;124(16):2479-86</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25185711</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2006 Oct 6;127(1):125-37</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16962653</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2005 Dec 9;280(49):40406-16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16221682</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Dev Cell. 2006 Dec;11(6):859-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17141160</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Mol Cell Biol. 2002 Sep;3(9):651-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12209125</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Interferon Cytokine Res. 2014 Apr;34(4):289-96</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24559173</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Cancer. 2006 Sep;6(9):729-34</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16915295</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2014 Aug 5;111(31):11377-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25049393</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Cycle. 2011 Jul 15;10(14):2305-16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21670596</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Cell Biol. 2009 May;29(10):2865-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19289497</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Org Biomol Chem. 2012 Nov 21;10(43):8570-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22832840</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Annu Rev Biochem. 1998;67:227-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9759489</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Annu Rev Immunol. 2001;19:623-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11244049</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2007 Jan 19;282(3):1757-68</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17114181</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Oncogene. 2012 Apr 19;31(16):2115-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21909137</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Res. 2009 Mar 1;69(5):1821-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19244117</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Dev Cell. 2007 Apr;12(4):487-502</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17419990</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood. 2003 Jun 15;101(12):4667-79</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12623839</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Biol. 2004 Jul 27;14(14):1296-302</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15268862</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Dev Cell. 2006 Oct;11(4):583-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16962829</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood. 2014 Dec 11;124(25):3699-708</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25342713</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Neurol. 2011 Apr;7(4):221-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21364522</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Canada</li>
<li>Pologne</li>
<li>États-Unis</li>
</country>
<region><li>Illinois</li>
</region>
</list>
<tree><noCountry><name sortKey="Jemielity, Jacek" sort="Jemielity, Jacek" uniqKey="Jemielity J" first="Jacek" last="Jemielity">Jacek Jemielity</name>
</noCountry>
<country name="États-Unis"><region name="Illinois"><name sortKey="Kroczynska, Barbara" sort="Kroczynska, Barbara" uniqKey="Kroczynska B" first="Barbara" last="Kroczynska">Barbara Kroczynska</name>
</region>
<name sortKey="Arslan, Ahmet Dirim" sort="Arslan, Ahmet Dirim" uniqKey="Arslan A" first="Ahmet Dirim" last="Arslan">Ahmet Dirim Arslan</name>
<name sortKey="Blyth, Gavin T" sort="Blyth, Gavin T" uniqKey="Blyth G" first="Gavin T" last="Blyth">Gavin T. Blyth</name>
<name sortKey="Kosciuczuk, Ewa M" sort="Kosciuczuk, Ewa M" uniqKey="Kosciuczuk E" first="Ewa M" last="Kosciuczuk">Ewa M. Kosciuczuk</name>
<name sortKey="Mehrotra, Swarna" sort="Mehrotra, Swarna" uniqKey="Mehrotra S" first="Swarna" last="Mehrotra">Swarna Mehrotra</name>
<name sortKey="Platanias, Leonidas C" sort="Platanias, Leonidas C" uniqKey="Platanias L" first="Leonidas C" last="Platanias">Leonidas C. Platanias</name>
<name sortKey="Rafidi, Robert L" sort="Rafidi, Robert L" uniqKey="Rafidi R" first="Robert L" last="Rafidi">Robert L. Rafidi</name>
<name sortKey="Saleiro, Diana" sort="Saleiro, Diana" uniqKey="Saleiro D" first="Diana" last="Saleiro">Diana Saleiro</name>
</country>
<country name="Canada"><noRegion><name sortKey="Majchrzak Kita, Beata" sort="Majchrzak Kita, Beata" uniqKey="Majchrzak Kita B" first="Beata" last="Majchrzak-Kita">Beata Majchrzak-Kita</name>
</noRegion>
<name sortKey="Fish, Eleanor N" sort="Fish, Eleanor N" uniqKey="Fish E" first="Eleanor N" last="Fish">Eleanor N. Fish</name>
</country>
<country name="Pologne"><noRegion><name sortKey="Warminska, Zofia" sort="Warminska, Zofia" uniqKey="Warminska Z" first="Zofia" last="Warminska">Zofia Warminska</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/BiopestPeptidV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001155 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001155 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    BiopestPeptidV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:26645692
   |texte=   Interferon γ (IFNγ) Signaling via Mechanistic Target of Rapamycin Complex 2 (mTORC2) and Regulatory Effects in the Generation of Type II Interferon Biological Responses.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:26645692" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a BiopestPeptidV1

This area was generated with Dilib version V0.6.38.
Data generation: Thu Nov 19 19:22:35 2020. Site generation: Thu Nov 19 19:33:26 2020

	Serveur d'exploration sur les peptides biopesticides
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les peptides biopesticides

Interferon γ (IFNγ) Signaling via Mechanistic Target of Rapamycin Complex 2 (mTORC2) and Regulatory Effects in the Generation of Type II Interferon Biological Responses.

Interferon γ (IFNγ) Signaling via Mechanistic Target of Rapamycin Complex 2 (mTORC2) and Regulatory Effects in the Generation of Type II Interferon Biological Responses.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki